Daiichi Sankyo Thermo Fisher Scientific, Daiichi Sankyo Partner to Develop Non-Small Cell Lung Cancer CDx The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi. ERS Genomics Licenses CRISPR-Cas9 IP to Daiichi Sankyo Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said. Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML. Invivoscribe Submits FLT3 Mutation CDx Assay to FDA Invivoscribe submitted the LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib. Invivoscribe Submits FLT3 Mutation Assay CDx to Japanese Regulators The company submitted the test to Japanese regulators for approval as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib. May 1, 2018 Thermo Fisher Inks New Pharma Partnerships to Expand CDx Use of Oncomine NGS Test Apr 17, 2017 HTG Molecular Inks Agreements With Daiichi Sankyo, Centre Léon Bérard Apr 25, 2016 MolecularMD Gets CE Mark for CDx Assay Used in Daiichi Sankyo Clinical Trial Mar 10, 2015 Study Provides 'Strong Evidence' Backing Warfarin Initiation PGx Testing; Adoption Impact Unclear Premium Apr 24, 2014 Agendia, Daiichi Sankyo Collaborate on Drug Assessment Feb 3, 2012 KineMed Inks Deal with Pfizer to Use Dynamic Proteomics Platform in Diabetes Drug Development Premium Aug 25, 2011 Roche Launches Melanoma Companion Dx in EU After FDA OK Last Week Premium Aug 17, 2011 FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma Premium Aug 17, 2011 FDA Approves Roche's Companion Dx and Drug for Melanoma Jul 1, 2011 Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche Premium May 18, 2011 Plexxikon, Roche File Rx/Dx Application for PLX4032, Cobas Mutation Test in Metastatic Melanoma Premium Mar 18, 2011 Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research Premium Jan 7, 2011 AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development Premium Sep 29, 2010 Kinaxo Inks Screening Deal with Daiichi Sankyo Sep 2, 2010 New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing Premium Jul 28, 2010 Medco to Compare Effient vs. PGx-Guided Plavix in Heart Patients on Prevacid Premium Oct 23, 2009 Morphosys, Daiichi Sankyo to Develop Therapeutic Antibodies Against Hospital-Acquired Infections Premium Oct 21, 2009 Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient Premium Mar 25, 2009 Gene Bridges Inks License with Japanese Pharma Firm Breaking News At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More FDA Grants Emergency Use Authorization for Northeastern University SARS-CoV-2 Test FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.